ArteraAI uses multimodal AI technology to analyze pathology images and patient data, providing personalized prognostic risk scores for cancer treatment.
What it is
ArteraAI is a medical software platform that applies multimodal AI to evaluate cancer cases, specifically focusing on prostate and breast cancer. The system examines existing H&E slide images alongside patient clinical records to generate individualized risk estimates and treatment response predictions.
Key features
- Multimodal AI platform combining clinical factors with digital pathology analysis
- Non-destructive testing that requires no additional tissue preparation or staining
- Rapid result turnaround delivered to certified laboratories within days
- Validated performance across diverse patient demographics and clinical trials
- FDA-cleared Software as a Medical Device for prostate cancer risk stratification
Who it's for
This platform is built for oncologists, urologists, pathologists, and clinicians who need prognostic insights to determine appropriate therapy plans for patients diagnosed with prostate or breast cancer. It also provides educational resources for patients seeking details regarding their diagnostic tests.
Pricing
Check the official website for current pricing.
Use cases
- Evaluate prostate cancer biopsy specimens
- Estimate patient risk for early-stage breast cancer
- Determine treatment responses for radiation therapy
Categories:
Similar to ArteraAI
More ArteraAI alternatives
Zephyr AI
OtherAI platform for precision medicine and oncology data
Zephyr AI translates fragmented clinical and biological information into actionable insights to advance therapeutic development and diagnostics.
